Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Circulating Tumor DNA in Merkel Cell Carcinoma: A Precision Biomarker for Recurrence Detection and Therapeutic Guidance.Journal of personalized medicine · 2026
   Review
2. Can liquid biopsy-guidedTranslational lung cancer research · 2019
   Article

Corrections and comments

• Comment on
  Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.2018

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.